ReviewTranslational cancer research2026
Thymic epithelial tumors: a narrative review of diagnostic and therapeutic advances.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Thymic epithelial tumors (TETs), comprising thymoma and thymic carcinoma, are rare mediastinal neoplasms that pose significant diagnostic and therapeutic challenges due to their complex anatomy and frequent association with paraneoplastic syndromes like myasthenia gravis (MG). This narrative review synthesizes recent advances in the multidisciplinary management of TETs, providing clinicians with a contemporary, tumor-specific overview. Methods: We conducted systematic literature searches across PubMed, Scopus, and Web of Science for publications from January 2018 to June 2024, focusing on high-impact studies (impact factor >3) with sample sizes >10 patients. Key terms included "thymoma", "thymic carcinoma", "minimally invasive thymectomy", "targeted therapy", and "immunotherapy". Content screening prioritized TETs-specific evidence. Key Content and Findings: Innovations in computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/CT (PET/CT) have enhanced TETs characterization, though differentiation of thymic hyperplasia remains challenging. Surgical management has shifted toward minimally invasive techniques [uniportal video-assisted thoracoscopic surgery (VATS), subxiphoid approach] and robotic surgery, reducing morbidity while maintaining oncological outcomes. For giant or invasive TETs, extended open techniques like clamshell incision remain indispensable. Systemic therapy advances include KIT/PIK3CA-targeted agents (imatinib, everolimus) showing modest efficacy, while programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors demonstrate 20-30% response rates in thymic carcinoma but are associated with a >50% risk of severe immune-related adverse events (irAEs). Platinum-based chemotherapy [cisplatin, doxorubicin, cyclophosphamide (CAP) regimen] remains standard for advanced disease. Multidisciplinary team (MDT) integration is fundamental, particularly for managing MG perioperatively. Conclusions: TETs management is evolving rapidly through technological and biological advances. Future progress hinges on: (I) validating artificial intelligence (AI)-driven imaging classifiers; (II) conducting randomized controlled trials (RCTs) comparing surgical approaches; (III) elucidating immunotherapy toxicity mechanisms; and (IV) developing predictive composite biomarkers integrating genomic, immunological, and clinical parameters to enable precision medicine while mitigating fatal toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.